Quince Therapeutics Form 3 for Brigette Roberts

Quince Therapeutics, Inc. filed an initial insider ownership report for Brigette Roberts, who is both a director and the company’s Chief Corporate Affairs Officer.

Rhea-AI Filing Summary

Quince Therapeutics, Inc. filed an initial insider ownership report for Brigette Roberts, who is both a director and the company’s Chief Corporate Affairs Officer. The Form 3 data shows no reported purchases, sales, or other transactions in the company’s securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Quince Therapeutics (QNCX) Form 3 for Brigette Roberts show?

The Form 3 identifies Brigette Roberts as a director and Chief Corporate Affairs Officer of Quince Therapeutics. It is an initial insider ownership report and shows no purchases, sales, or other transactions in the company’s securities in the provided data.

Did Brigette Roberts buy or sell any Quince Therapeutics (QNCX) shares in this Form 3?

No, the Form 3 data reports zero buy and zero sell transactions for Brigette Roberts. It functions only as an initial statement of insider status rather than a record of trading activity in Quince Therapeutics stock.

What insider role does Brigette Roberts hold at Quince Therapeutics (QNCX)?

Brigette Roberts is reported as both a director and an officer of Quince Therapeutics, serving as Chief Corporate Affairs Officer. This dual role means she is considered a reporting person for insider disclosure under SEC rules, triggering the Form 3 filing requirement.

Why is a Form 3 filed for a Quince Therapeutics (QNCX) insider?

A Form 3 is filed when someone becomes a reporting insider, such as a director or certain officers. For Quince Therapeutics, it records Brigette Roberts’ status as a director and Chief Corporate Affairs Officer and establishes a baseline before any future reported trades.

Does the Quince Therapeutics (QNCX) Form 3 include derivative securities for Brigette Roberts?

No, the derivative securities section in the provided Form 3 data is empty. There are no listed options, warrants, or other derivative positions reported for Brigette Roberts in this initial ownership statement for Quince Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 05:28 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Roberts Brigette

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/18/2026

3. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Corp. Affairs Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney. This Form 3 is being filed late due to an administrative delay in obtaining the Reporting Person's EDGAR filing credentials.

No securities are beneficially owned.

	/s/ Brendan Hannah, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)